Acute ST-segment elevation myocardial infarction

被引:85
作者
Goodman, Shaun G. [1 ]
Menon, Venu [2 ]
Cannon, Christopher P. [3 ]
Steg, Gabriel [4 ]
Ohman, E. Magnus [5 ]
Harrington, Robert A. [5 ]
机构
[1] Univ Toronto, Michaels Hosp, Toronto, ON, Canada
[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Hop Bichat Claude Bernard, F-75877 Paris, France
[5] Duke Univ, Med Ctr, Durham, NC USA
关键词
anticoagulant drugs; antiplatelet drugs; fibrinolytic therapy; myocardial infarction;
D O I
10.1378/chest.08-0665
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
This chapter about fibrinolytic, antiplatelet, and antithrombin treatment for acute ST-segment elevation (STE) myocardial infaretion (MI) is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade I recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values may lead to different choices (for a full understanding of the grading see the chapter by Guyatt et al, CHEST 2008; 133[suppl]:123S-131S). Among the key recommendations in this chapter are the following: for patients with ischemic symptoms characteristic of acute MI of <= 12 h in duration and persistent STE, we recommend that all undergo rapid evaluation for reperfusion (primary percutaneous coronary intervention [PCI] or fibrinolytic) therapy and have a reperfusion strategy implemented promptly after contact with the health-care system (Grade 1A). For patients with ischemic symptoms characteristic of acute MI of <= 12 h in duration and persistent STE, we recommend administration of streptokinase, anistreplase, alteplase, reteplase, or tenecteplase over no fibrinolytic therapy (all Grade 1A). For patients with symptom duration <= 6 h, we recommend the administration of alteplase or tenecteplase over streptokinase (both Grade 1A). We recommend aspirin over no aspirin therapy followed by indefinite therapy (Grade 1A); we also recommend clopidogrel in addition to aspirin for up to 28 days (Grade 1A). In addition to aspirin and other antiplatelet therapies, we recommend the use of antithrombin therapy (eg, unfractionated heparin (UFH), enoxaparin, or fondaparinux) over no antithrombin therapy (Grade 1A), including for those patients receiving fibrinolysis (and regardless of which lytic agent is administered), primary PCI, or patients not receiving reperfusion therapy.
引用
收藏
页码:708S / 775S
页数:68
相关论文
共 263 条
[1]   Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide, monotherapy in acute Myocardial Infarction (ADVANCE MI) trial [J].
Adgey, J ;
Ardissino, D ;
Armstrong, P ;
Berger, P ;
Betriu, A ;
Beyar, R ;
Bode, C ;
Braunwald, E ;
Brindis, R ;
Brogan, G ;
Buller, C ;
Califf, R ;
Casterella, P ;
Gibler, WB ;
Giugliano, R ;
Goldstein, P ;
Granger, C ;
Guetta, V ;
Harrington, R ;
Herrmann, H ;
Hochman, J ;
Hoekstra, J ;
Kleiman, N ;
Labinaz, M ;
Langer, A ;
Montalescot, G ;
Ohman, EM ;
O'Neill, W ;
Pollack, C ;
Roe, M ;
Satler, L ;
Schweiger, M ;
Simoons, M ;
Steg, G ;
Tanguay, JF ;
Van de Werf, F ;
Wallentin, L ;
Zeymer, U .
AMERICAN HEART JOURNAL, 2005, 150 (01) :116-122
[2]  
[Anonymous], 1987, Lancet, V2, P871
[3]  
[Anonymous], 1987, Eur Heart J, V8, P634
[4]  
[Anonymous], 1988, Lancet, V1, P545
[5]  
[Anonymous], 1990, LANCET, V336, P65
[6]  
[Anonymous], 1988, LANCET, V2, P349
[7]  
[Anonymous], 1986, Lancet, V1, P397
[8]  
ANTMAN E, ACC AHA GUIDELINES M
[9]   Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14 [J].
Antman, EM ;
Gibson, CM ;
de Lemos, JA ;
Giugliano, RP ;
McCabe, CH ;
Coussement, P ;
Menown, I ;
Nienaber, CA ;
Rehders, TC ;
Frey, NJ ;
Van der Wieken, R ;
Andresen, D ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
EUROPEAN HEART JOURNAL, 2000, 21 (23) :1944-1953
[10]   HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].
ANTMAN, EM .
CIRCULATION, 1994, 90 (04) :1624-1630